Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results

Vijaya Raj Bhatt; Hagop Kantarjian; Jorge E. Cortes; Farhad Ravandi; Gautam Borthakur

doi:10.1016/j.clml.2012.11.006

Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results

Vijaya Raj Bhatt
, Hagop Kantarjian
, Jorge E. Cortes
, Farhad Ravandi
, Gautam Borthakur

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

Original language	English (US)
Pages (from-to)	153-158
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.clml.2012.11.006
State	Published - Apr 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chemotherapy
High-dose cytarabine
Inversion (16)
Response
Translocation (8;21)

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2012.11.006

Cite this

@article{221ddd64615d427994f62432c83a5ca4,

title = "Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results",

abstract = "Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40\% to 50\% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.",

keywords = "Chemotherapy, High-dose cytarabine, Inversion (16), Response, Translocation (8;21)",

author = "Bhatt, \{Vijaya Raj\} and Hagop Kantarjian and Cortes, \{Jorge E.\} and Farhad Ravandi and Gautam Borthakur",

note = "Funding Information: This research is supported in part by the National Institutes of Health through M.D. Anderson's Cancer Center Support grant CA016672 and National Institutes of Health leukemia SPORE P01(CA055164) .",

year = "2013",

month = apr,

doi = "10.1016/j.clml.2012.11.006",

language = "English (US)",

volume = "13",

pages = "153--158",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Therapy of core binding factor acute myeloid leukemia

T2 - Incremental improvements toward better long-term results

AU - Bhatt, Vijaya Raj

AU - Kantarjian, Hagop

AU - Cortes, Jorge E.

AU - Ravandi, Farhad

AU - Borthakur, Gautam

N1 - Funding Information: This research is supported in part by the National Institutes of Health through M.D. Anderson's Cancer Center Support grant CA016672 and National Institutes of Health leukemia SPORE P01(CA055164) .

PY - 2013/4

Y1 - 2013/4

N2 - Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

AB - Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

KW - Chemotherapy

KW - High-dose cytarabine

KW - Inversion (16)

KW - Response

KW - Translocation (8;21)

UR - https://www.scopus.com/pages/publications/84877314816

UR - https://www.scopus.com/pages/publications/84877314816#tab=citedBy

U2 - 10.1016/j.clml.2012.11.006

DO - 10.1016/j.clml.2012.11.006

M3 - Article

C2 - 23266036

AN - SCOPUS:84877314816

SN - 2152-2650

VL - 13

SP - 153

EP - 158

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 2

ER -

Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this